Peptides for Muscle Growth 2026: Recovery, Mitochondria and Research Mechanisms

In short: Peptides for muscle growth in the research context

“Peptides for muscle growth” is a search query that in reality covers three distinct areas of research, regeneration of damaged muscle fibres, mitochondrial function (ATP production, endurance) and body composition (the ratio of muscle to adipose tissue).

Unlike classical anabolics (testosterone, SARMs, growth hormone), research peptides do not act directly anabolically. Their influence on muscle is indirect, via faster regeneration of micro-tears, healthier mitochondria and selective lipolysis without loss of muscle mass.

Briefly, the peptides investigated in the research literature in the context of muscle performance:

• TB-500, Thymosin β-4 fragment, muscle and tendon regeneration via mobilisation of progenitors
• BPC-157, healing of muscle fibres, angiogenesis, a complementary partner to TB-500
• MOTS-c, a mitochondrial 16-amino-acid peptide, AMPK activation, endurance model
• HGH Fragment 176-191, C-terminal fragment of growth hormone, lipolysis without an IGF-1 signal
• NAD+, the mitochondrial cofactor for ATP, activation of sirtuins (SIRT1/3)
• AOD-9604, a modified lipolytic fragment, compositional research

Molequa® deliberately does not offer classical anabolic peptides (Ipamorelin, CJC-1295, MK-677, IGF-1 LR3). The catalogue is focused on regenerative and mitochondrial science, the area where the preclinical literature is strongest and regulatory risks lowest.

What “peptides for muscle growth” mean in the research context

In the research literature these peptides do not act like anabolics. Testosterone and SARMs directly raise muscle protein synthesis through androgen receptors or the IGF-1 axis; the peptides discussed here work indirectly, by improving the conditions in which a muscle fibre recovers and adapts. That distinction is why the search term is misleading.

In popular discussion, “peptides for muscle growth” are commonly equated with anabolics, substances that directly increase muscle-protein synthesis (MPS) via androgen receptors or via the IGF-1 axis. This is a misleading oversimplification.

In the research peptide literature, the term “muscle growth” is understood more broadly, as a complex process consisting of several partial mechanisms:

1. Mechanical loading causes micro-tears in muscle fibres
2. The inflammatory response activates satellite cells (myogenic progenitors)
3. Angiogenesis delivers more blood, oxygen and nutrients to the site of healing
4. Fibroblast migration and collagen synthesis restore the structure
5. Mitochondrial adaptation increases the oxidative capacity of fibres
6. Metabolic optimisation shifts the muscle/fat ratio in favour of active mass

Classical anabolics (testosterone, SARMs) act on points 1 and 4, they directly stimulate transcription of genes for muscle proteins. Research peptides such as TB-500, BPC-157 and MOTS-c act on points 2, 3, 5 and 6, they support the environment in which the muscle fibre grows more efficiently.

For the researcher, this distinction is critical. A peptide that accelerates the healing of a muscle contusion by 40 % is not a “weaker version of testosterone”, it is a qualitatively different molecule with its own place in regenerative and metabolic science.

Categories of peptides investigated for muscle performance

The literature splits them into three groups by dominant mechanism: regenerative peptides that shorten recovery, mitochondrial peptides that improve energy metabolism, and compositional peptides that act on fat metabolism. None of the three builds muscle directly, which is precisely why they are studied alongside training rather than instead of it.

In the research literature, peptides relevant to muscle performance are divided into three principal categories according to the dominant mechanism.

1. Regenerative peptides

Objective: to shorten recovery time between training stimuli in animal models and to accelerate healing of contusion or transection injuries.

Representatives: TB-500 (Thymosin β-4 fragment), BPC-157, GHK-Cu (cutaneous models).

Mechanism: angiogenesis (new vessels → more blood and nutrients), mobilisation of satellite cells, collagen synthesis, reduction of inflammatory stress.

2. Mitochondrial peptides

Objective: to increase aerobic capacity and ATP production, which in endurance models extends time to exhaustion and reduces lactate accumulation.

Representatives: MOTS-c, NAD+ (technically a nucleotide, but functionally in this category), Humanin, SS-31 (Elamipretide).

Mechanism: activation of AMPK (the cellular sensor of energy status), increased β-oxidation of fatty acids, protection of the mitochondrial membrane against oxidative stress.

3. Compositional peptides

Objective: to selectively break down adipose tissue and preserve muscle mass, that is, to shift body composition without a classical caloric deficit, which often leads to loss of muscle.

Representatives: HGH Fragment 176-191, AOD-9604, in part tesamorelin (visceral fat).

Mechanism: selective lipolysis via the β3-adrenergic receptor, activation of hormone-sensitive lipase, oxidation of released fatty acids without stimulation of the IGF-1 axis.

This tripartite classification is important for understanding why the Molequa® catalogue looks the way it does, in each of the three categories the best-documented representative is included.

TB-500, Thymosin β-4 for muscle regeneration

TB-500 is a 17-amino-acid fragment (segment 4 to 23) of natural Thymosin β-4 (Tβ4), a 43-amino-acid protein isolated in 1981 by Allan Goldstein from the thymus. It does not raise muscle protein synthesis; it affects how fast a damaged fibre is rebuilt, which is what contusion and microtear models actually measure.

Discovery and molecular context

Goldstein’s team originally investigated Tβ4 as an immunological regulator. It rapidly became clear, however, that Tβ4 is present practically everywhere in the body, it is one of the most abundant intracellular mammalian proteins. The question then arose: why does the cell maintain such a large pool of this molecule?

The answer arrived in the 1990s. Tβ4 is the principal sequesterer of G-actin, the monomeric form of actin, which serves as the building block of the cytoskeleton. Without Tβ4, G-actin would spontaneously polymerise and the cell would lose the ability to dynamically rearrange its shape.

For muscle this is critical. Regeneration of muscle fibres requires massive cytoskeletal reorganisation, satellite cells must divide, migrate to the site of damage, fuse with the existing fibre and rearrange the contractile apparatus.

Key mechanisms for muscle

1. G-actin sequestration and cytoskeletal dynamics, Tβ4 maintains a reserve of G-actin ready for rapid polymerisation in the regeneration phase
2. Mobilisation of progenitors, Tβ4 chemoattractively mobilises both endothelial and myogenic progenitor cells from the bone marrow
3. Angiogenesis, a secondary effect via VEGF, important for the supply of nutrients to the healing muscle
4. Anti-inflammatory effect via NF-κB, dampening the excess inflammation that would otherwise slow regeneration
5. Anti-apoptotic effect via integrin-linked kinase (ILK), protecting newly awakened satellite cells from programmed death

Demonstrated applications

Goldstein, Hannappel and Kleinman (2005) in a review in Trends in Molecular Medicine PubMed 16099219 summarised evidence that Tβ4 “moonlights”, beyond its primary actin function it actively repairs damaged tissues.

Smart et al. (2007) in Nature PubMed 17108969 demonstrated that Tβ4 can mobilise adult epicardial progenitor cells in a mouse model of infarction, a mechanism that is in part transferable to skeletal muscle, where satellite cells share some molecular pathways with epicardial progenitors.

For the researcher focused on musculoskeletal models, TB-500 is the primary choice whenever the objective is to accelerate recovery after mechanical loading or contusion trauma.

A complete overview of mechanisms, dosing and safety profile is provided on the dedicated TB-500 product page.

BPC-157, healing of muscle fibres and tendons

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide isolated in 1991 in Zagreb under the leadership of Prof. Predrag Sikiric. The starting material was a larger protein from gastric juice, Sikiric’s group sought an endogenous factor that protects the mucosa from its own acid.

Over 30+ years of research, BPC-157 has moved far beyond gastroenterology, it is today among the most-studied regenerative peptides at all, with more than 200 peer-reviewed publications.

Why BPC-157 is relevant for muscle

The muscle fibre is structurally complex, it combines contractile proteins, extracellular matrix, capillaries and innervation. Regeneration of micro-tears requires a coordinated process in which the vascular network must be restored, fibroblasts must deliver collagen and satellite cells must reconstruct the contractile apparatus.

In research models, BPC-157:

1. Induces angiogenesis via VEGFR2 (the vascular endothelial growth factor receptor), new vessels deliver more oxygen and nutrients to the muscle
2. Activates the FAK-paxillin pathway, leading to migration of fibroblasts and tenocytes to the site of damage
3. Modulates nitric oxide (NO), bidirectional regulation of the NO system, beneficial for muscular perfusion
4. Increases the sensitivity of tissues to growth hormone through up-regulation of GH receptors (without any intrinsic GH stimulation)

Ideal for muscle micro-tears and tendons

Chang et al. (2011) in the Journal of Applied Physiology PubMed 21030672 demonstrated a promoting effect of BPC-157 on tendon healing, acceleration of tenocyte proliferation, up-regulation of FAK-paxillin and more pronounced synthesis of type I collagen.

Sikiric et al. (2018) in Current Pharmaceutical Design PubMed 29998800 in a review described BPC-157 as a pleiotropic regenerator acting simultaneously on the vascular, tissue and neurological components of healing.

For research models of muscle micro-tears, contusions, transection injuries and chronic tendinopathies, BPC-157 is the preferred partner to TB-500, the mechanisms complement rather than overlap (see the comparative article BPC-157 vs TB-500).

A complete overview is provided on the BPC-157 product page.

MOTS-c, a mitochondrial peptide for endurance

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid peptide unique in its origin, it is encoded by the mitochondrial genome (not by nuclear DNA), specifically by an open reading frame within the 12S rRNA sequence. In endurance models it extended time to exhaustion, meaning it acts through energy supply rather than through muscle mass.

Discovery, Lee et al., Cell Metabolism 2015

Lee, Kim, Cobb et al. (2015) in Cell Metabolism PubMed 25738459 first described MOTS-c as a mitochondrially derived peptide regulating metabolic homeostasis. The authors demonstrated that MOTS-c:

• Reduces insulin resistance in a mouse model of diet-induced obesity
• Activates AMPK, the principal cellular sensor of energy status
• Increases β-oxidation of fatty acids, muscle burns more fat than glucose
• Reduces accumulation of visceral fat

AMPK, why it is relevant for endurance

AMPK (AMP-activated protein kinase) is the cell’s molecular “low-energy alarm”. When ATP levels fall (for example during endurance loading), AMPK is activated and triggers a cascade that:

• Increases glucose uptake via GLUT4 transporters in the muscle fibre
• Increases oxidation of fatty acids, the preferred fuel for endurance
• Stimulates mitochondrial biogenesis via PGC-1α, the muscle creates more mitochondria
• Suppresses energy-demanding anabolic processes (for example protein synthesis when energy is scarce)

In research models of endurance performance (rat treadmill, swimming tests) MOTS-c extended time to exhaustion and reduced lactate levels. This makes MOTS-c a primary candidate for research on aerobic capacity.

For the researcher, MOTS-c is relevant whenever the objective is to investigate mitochondrial function, endurance and metabolic flexibility, the areas where regenerative peptides such as TB-500 and BPC-157 do not have a dominant mechanism.

A complete overview is provided on the MOTS-c product page.

HGH Fragment 176-191, a lipolytic fragment

HGH Fragment 176-191 is the C-terminal 16-amino-acid fragment of human growth hormone (hGH, 191 amino acids). The sequence corresponds to positions 176 to 191 in the native molecule. That is precisely why it does not raise IGF-1 levels, which separates it from whole growth hormone.

Why it is of interest for muscle/compositional models

Human growth hormone possesses several functional domains. Historically it was associated primarily with growth effects via the IGF-1 axis (stimulation of tissue, cartilage and bone growth). It has emerged, however, that the lipolytic effect, the capacity to activate fat breakdown, is separated from the anabolic IGF-1 signal and localised to the C-terminal fragment.

Wade and colleagues (1979) in Int J Pept Protein Res PubMed 429095 first described that a synthetic C-terminal fragment of hGH produces hyperglycaemic and lipolytic activity without the classical growth effects. This observation later led to research interest in the fragment itself as a selective lipolytic agent.

Selective lipolysis without the IGF-1 axis

HGH Fragment 176-191:

• Activates the β3-adrenergic receptor in adipose tissue
• Stimulates hormone-sensitive lipase (HSL), the enzyme that cleaves triacylglycerols into free fatty acids and glycerol
• Increases β-oxidation of the released fatty acids
• Does not raise IGF-1, that is, it has no anabolic effect on cartilage, bones or internal organs associated with classical excessive hGH signalling

The compositional angle

For the researcher, HGH Fragment is relevant in studies where the objective is to shift body composition, that is, to reduce the fat ratio while preserving muscle mass. This differs from a classical caloric deficit, which often also leads to losses of muscle tissue.

The combination of HGH Fragment (lipolysis) + regenerative peptides (preservation of muscle through better recovery) is described in the research literature as a compositional stack, two mechanisms that together synergistically shift the muscle/fat ratio.

A complete overview is provided on the HGH Fragment 176-191 product page.

NAD+ for mitochondrial energy

NAD+ (nicotinamide adenine dinucleotide) is technically not a peptide, it is a nucleotide, a coenzyme derived from niacin (vitamin B3). In the context of performance and mitochondrial research, however, it is functionally in the same category as MOTS-c, it regulates energy metabolism and influences muscle performance.

Why NAD+ is critical for muscle

NAD+ is the principal cofactor for more than 500 enzymatic reactions, most of which take place directly within the mitochondria:

• The Krebs cycle, NAD+ accepts electrons from acetyl-CoA and becomes NADH
• The electron transport chain, NADH transfers electrons to complex I, driving ATP synthesis
• β-oxidation of fatty acids, requires NAD+ in each cycle
• Activation of sirtuins (SIRT1, SIRT3), NAD-dependent deacetylases that regulate mitochondrial biogenesis and antioxidant defence

With age, NAD+ levels in tissues decline, one of the molecular causes of mitochondrial dysfunction and reduced aerobic capacity. Supplementation of NAD+ (or its precursors NMN, NR) is therefore an area of intense research in gerontology and sports science.

Sirtuins SIRT1 and SIRT3

• SIRT1, deacetylates PGC-1α, activating mitochondrial biogenesis (the cell creates more mitochondria)
• SIRT3, deacetylates mitochondrial enzymes of the Krebs cycle and electron transport, increasing their efficiency

In research models of endurance performance, NAD+ supplementation increased the number of mitochondria in muscle fibres, reduced oxidative stress and extended time to exhaustion.

A complete overview is provided on the NAD+ product page.

AOD-9604 in compositional research

AOD-9604 (Anti-Obesity Drug-9604) is a modified analogue of the C-terminal fragment of hGH, specifically a modification of the 177-191 sequence with an added tyrosine residue at the N-terminus for stability. It was developed by the Australian company Metabolic Pharmaceuticals as a selective anti-obesity agent.

Development history

Heffernan et al. (2001) in Endocrinology PubMed 11713213 demonstrated that AOD9604 shares the lipolytic profile of the C-terminal fragment of hGH but lacks its hyperglycaemic effect, making it a more attractive candidate for clinical development.

Metabolic Pharmaceuticals advanced AOD-9604 into clinical studies for obesity, but in 2014 the FDA rejected the NDI notification (New Dietary Ingredient) for the position of AOD-9604 as a dietary supplement. The molecule has since remained in the research space.

A profile similar to HGH Fragment 176-191

The mechanism of AOD-9604 is very similar to that of HGH Fragment 176-191:

• Selective lipolysis via β3-adrenergic signalling
• Activation of hormone-sensitive lipase
• Without stimulation of the IGF-1 axis, thus without anabolic/growth effects
• Without a hyperglycaemic effect (in this AOD-9604 differs slightly from the original HGH Fragment)

For the researcher, AOD-9604 is an alternative to HGH Fragment where the objective is to investigate lipolysis with an even more selective profile (without the glycaemic effect).

A complete overview is provided on the AOD-9604 product page.

Comparison table: TB-500 vs BPC-157 vs MOTS-c vs HGH Fragment

Side by side the four differ in category and mechanism, not in strength. TB-500 and BPC-157 are regenerative, MOTS-c is mitochondrial and HGH Fragment 176-191 is compositional. Reading the table by length and origin rather than by expected effect is the useful way, because the effect depends on the research model.

How to read the table: The peptides in the first two columns (TB-500, BPC-157) complement one another, they form the canonical regenerative combination. MOTS-c and NAD+ cover the mitochondrial axis. HGH Fragment and AOD-9604 cover the compositional axis. For a comprehensive research stack, the research literature refers to a combination of one representative from each category.

Why Ipamorelin, CJC-1295 and MK-677 are not in the Molequa catalogue

They are absent deliberately. Ipamorelin, CJC-1295 and MK-677 are growth hormone secretagogues, which places them in a different regulatory and anti-doping category and moves the catalogue toward performance claims we are not permitted to make. The catalogue focuses instead on regenerative and mitochondrial peptides, where the preclinical evidence is strongest.

This question appears in every second email from the research community. The answer is deliberate and strategic.

Regulatory and WADA context

Ipamorelin, CJC-1295, MK-677 (Ibutamoren) and IGF-1 LR3 are peptides (in the case of MK-677 a non-peptide secretagogue) that directly or indirectly stimulate the growth-hormone axis, that is, they increase endogenous production of hGH and subsequently of IGF-1.

From a regulatory point of view they are very high-risk:

• WADA classification S2 (Peptide Hormones, Growth Factors, Related Substances), complete prohibition for professional athletes
• In many jurisdictions they are classified as experimental substances with strict distribution restrictions
• Clinically they are not approved as medicinal products (with the exception of tesamorelin for HIV-associated lipodystrophy)
• Most real-world use is by the off-label bodybuilding community, not academic research

Scientific and ethical context

As a European RUO supplier for laboratory research, Molequa® has a strategic focus on peptides where:

1. Preclinical literature is strongest (TB-500 and BPC-157 together have 300+ publications)
2. Regulatory risks are lowest (regenerative and mitochondrial peptides do not have the same degree of doping misuse)
3. The scientific profile is clinically relevant, regeneration and metabolic health are the areas where peptides can bring a truly new mechanism, not merely imitate classical anabolics

A catalogue focused on recovery, mitochondria and metabolic optimisation is therefore a choice, not a compromise. For the researcher looking for an anabolic imitation of testosterone, Molequa is the wrong address. For the researcher looking for quality TB-500, BPC-157, MOTS-c or HGH Fragment with HPLC ≥ 99 %, an independent CoA and EU delivery, Molequa is the optimal choice.

WADA classification of peptides relevant to sport

Every peptide discussed here appears on the WADA Prohibited List, and stating that plainly matters more than omitting it. TB-500, BPC-157, growth hormone secretagogues and HGH fragments all fall under prohibited categories for athletes in and out of competition. Research use is a separate question from competitive eligibility.

For transparency towards the research community it is important to state the WADA status of all peptides discussed in this article. WADA (World Anti-Doping Agency) classifies substances into categories of differing severity.

Explanation of categories:

• S0 (Non-Approved Substances), substances that have no approval as a medicinal product in any regulatory jurisdiction. WADA prohibits them categorically regardless of mechanism.
• S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), substances that mimic or modulate the signalling of peptide hormones (notably the GH axis, EPO, insulin).

For professional athletes the complete prohibition applies to all peptides with S0/S2 classifications, both in and out of competition. WADA has developed LC-MS/MS detection methods for most clinically relevant peptides.

In the research context (RUO, Research Use Only) the WADA classification does not apply directly, laboratory research is not subject to doping rules. It is, however, relevant when publishing results in sports science and when ethics committees review studies involving human volunteers.

Frequently asked questions about peptides for muscle performance

These questions answer the most frequent searches relating to research on peptides in the context of muscle performance, regeneration and metabolic optimisation.

Which peptides are most researched for muscle regeneration?

TB-500 (Thymosin β-4 fragment) and BPC-157 are among the most-researched pair of regenerative peptides in the preclinical literature. TB-500 dominates in mobilisation of progenitor cells and G-actin sequestration; BPC-157 in VEGFR2 angiogenesis and FAK-paxillin migration of fibroblasts. Sikiric et al. (2018) PubMed 29998800 describes the combination as complementary, the mechanisms complement rather than overlap.

What is the difference between TB-500 and BPC-157 in muscle research?

TB-500 targets cytoskeletal reorganisation via G-actin sequestration and mobilises progenitor cells from the bone marrow, it is stronger in models where the delivery of new cells is required. BPC-157 targets angiogenesis via VEGFR2 and migration of fibroblasts and tenocytes, it is stronger in models of muscle-fibre micro-tears and tendon lesions. A detailed comparison is available in the separate article BPC-157 vs TB-500.

Do research peptides work like anabolics?

Not directly. Classical anabolics (testosterone, SARMs, IGF-1) directly activate androgen receptors or the IGF-1 axis and directly stimulate the synthesis of muscle proteins. Research peptides such as TB-500, BPC-157 or MOTS-c act indirectly, via better regeneration, angiogenesis, mitochondrial function and metabolic flexibility. Their influence on muscle is real but qualitatively distinct from classical anabolics.

How does MOTS-c support an endurance research model?

MOTS-c activates AMPK (the cellular sensor of energy status), leading in the muscle fibre to increased β-oxidation of fatty acids, stimulation of mitochondrial biogenesis via PGC-1α and reduction of insulin resistance. Lee et al. (2015) in Cell Metabolism PubMed 25738459 demonstrated that MOTS-c reduces diet-induced obesity and improves metabolic homeostasis. In research endurance models it extends time to exhaustion.

Why is HGH Fragment different from classical HGH?

HGH Fragment 176-191 contains only the C-terminal domain of human growth hormone, responsible for the lipolytic effect (fat breakdown). It does not activate the IGF-1 axis, that is, it has no anabolic/growth effects on cartilage, bone or internal organs associated with classical hGH signalling. For compositional research this is an attractive profile, selective lipolysis without growth-related side effects.

What is the WADA status of peptides for sport?

BPC-157 has been listed in category S0 (Non-Approved Substances) since 1 January 2022. TB-500, HGH Fragment 176-191 and AOD-9604 are in category S2 (Peptide Hormones, Growth Factors, Related Substances). For professional athletes the complete prohibition applies both in and out of competition. MOTS-c is currently (2026) explicitly unclassified, a grey zone. NAD+, as an endogenous cofactor, is not classified.

Where can research peptides for performance studies be purchased in the EU?

Browse all research peptides with documented purity in the Molequa® catalogue, with a certificate of analysis for every batch.

Research peptides for laboratory performance and regeneration studies in the EU are offered by Molequa® with FedEx delivery within 1 to 3 business days across Slovakia, the Czech Republic and the EU. The catalogue includes TB-500, BPC-157, MOTS-c, HGH Fragment 176-191, NAD+ and AOD-9604, all with HPLC purity ≥ 99 %, an independent certificate of analysis (CoA) and LAL endotoxin testing. Molequa® products are sold exclusively for laboratory scientific research (RUO).

Key scientific figures and citations

Research peptides relevant for muscle regeneration, mitochondrial function and body composition have varying levels of preclinical evidence. The following key figures and references from the peer-reviewed literature are provided.

“The mitochondrial-derived peptide MOTS-c targets AMPK to promote metabolic homeostasis. Its actions extend from improved glucose disposal to enhanced skeletal muscle fatty acid oxidation, positioning MOTS-c as a metabolic regulator relevant to endurance physiology.” Lee C. et al. (2015), Cell Metabolism 21(3):443–454, PubMed 25738459

Statistics from preclinical/clinical literature

• TB-500: 17-amino-acid fragment (segment 4–23) of natural Thymosin β-4 (43 AA, ~4,963 Da), isolated by Goldstein in 1981
• BPC-157: 15 amino acids, 1,419.53 Da, identified 1991 in Zagreb (P. Sikiric group), 200+ publications
• MOTS-c: 16-amino-acid peptide encoded by the mitochondrial genome (12S rRNA ORF), described 2015 (Lee et al.)
• HGH Fragment 176-191: 16-amino-acid C-terminal fragment of the 191-AA human growth hormone, lipolytic profile without IGF-1 stimulation
• NAD+: nicotinamide adenine dinucleotide, cofactor for 500+ enzymatic reactions, key to the Krebs cycle and the electron transport chain
• AOD-9604: modified analogue of the C-terminal fragment of hGH (sequence 177-191 + N-tyrosine), Metabolic Pharmaceuticals, FDA NDI rejection 2014

Reference sources (PubMed)

1. Goldstein AL., Hannappel E., Kleinman HK. (2005). “Thymosin β4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med 11(9):421–429. PubMed 16099219
2. Smart N. et al. (2007). “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.” Nature 445(7124):177–182. PubMed 17108969
3. Sikiric P. et al. (2018). “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing.” Curr Pharm Des 24(18):1972–1989. PubMed 29998800
4. Chang CH. et al. (2011). “The promoting effect of pentadecapeptide BPC 157 on tendon healing.” J Appl Physiol 110(3):774–780. PubMed 21030672
5. Lee C. et al. (2015). “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab 21(3):443–454. PubMed 25738459
6. Ng FM., Bornstein J. (1978). “Hyperglycemic action of synthetic C-terminal fragment of hGH.” Diabetes 27(8):857–863. PubMed 429095
7. Heffernan MA. et al. (2001). “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism.” Endocrinology 142(12):5182–5188. PubMed 11713213

Scope of this article: This article summarises the scientific literature on peptides investigated in the context of muscle regeneration, mitochondrial function and body composition. It does not present therapeutic claims or recommendations for human use. Molequa® products are sold exclusively for laboratory scientific research (RUO), they are not a medicine, dietary supplement or intended for human or animal consumption.

Regulatory status

The peptides mentioned in this article (TB-500, BPC-157, MOTS-c, HGH Fragment 176-191, NAD+, AOD-9604) and all Molequa® products are intended exclusively for research and scientific purposes (RUO, Research Use Only). They are not a medicine, dietary supplement, cosmetic product or foodstuff. They are not intended for human or animal consumption. Sale is restricted to qualified researchers, academic institutions and laboratories. Before any handling, the relevant scientific literature should be consulted and applicable legislation in the user’s jurisdiction should be observed. Most of the peptides mentioned are prohibited by WADA for professional athletes.

How batch quality is verified

Every Molequa® batch is analysed by the independent laboratory Janoshik Analytical. The batch certificate states HPLC purity and confirms identity by mass spectrometry, and it is available on the product page before purchase rather than after.

An in-house analysis by the seller and an analysis by an independent laboratory are not the same evidence. A purity figure with no chromatogram attached is a claim, not proof.

Legal notice

The peptides mentioned in this article (TB-500, BPC-157, MOTS-c, HGH Fragment 176-191, NAD+, AOD-9604) and all Molequa® products are intended exclusively for research and scientific purposes (RUO, Research Use Only). They are not a medicine, dietary supplement, cosmetic product or foodstuff. They are not intended for human or animal consumption. Sale is restricted to qualified researchers, academic institutions and laboratories. Before any handling, the relevant scientific literature should be consulted and applicable legislation in the user’s jurisdiction should be observed. Most of the peptides mentioned are prohibited by WADA for professional athletes. The product is sold strictly for laboratory scientific research (RUO).

Author: Molequa® Research Team Publication date: 2 July 2026 Last update: July 2026 Reading time: ~12 min